Notice NOT-NS-18-087 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-18-011 from the NIH Guide for Grants and Contracts. This FOA invites new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components. CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans.

Notice NOT-ES-18-009 from the NIH Guide for Grants and Contracts

Notice NOT-AG-18-025 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-19-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation G: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 application for projects aimed at identifying best practices to improve case ascertainment and follow-up care of hereditary cancers, with the goal of improving prevention and detection.

Funding Opportunity PAR-18-900 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK X02 and R61/R33 FOAs are not intended to support clinical trials. The RISK program will support the two main scientific areas of NIAMS mission, 1) musculoskeletal diseases and 2) the skin and rheumatic diseases. This X02 pre-application and the companion R61/R33 (RFA-AR-19-013) encourage applications related to musculoskeletal diseases. The X02 pre-application is the highly recommended (not required) first step in the application process for the companion R61/R33 (RFA-AR-19-013). Potential applicants should read both FOAs. Investigators whose X02 pre-applications are evaluated to be highly innovative and most relevant to the RISK program will be notified of the opportunity to submit an R61/R33 application under RFA-AR-19-013.

Notice NOT-HL-18-647 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-898 from the NIH Guide for Grants and Contracts. NIDDK utilizes High Impact, Interdisciplinary Science (RC2) grants to support projects that will lay the foundation for new fields of investigation within the mission of NIDDK. The RC2 is envisioned to use an interdisciplinary approach to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This targeted FOA specifically seeks to generate scientific advancements addressing the role of the autonomic nervous system in the regulation of peripheral metabolism and its role in diabetes, obesity and related metabolic disease. Interdisciplinary teams may propose to develop resources in the form of novel tools or methodologies that when applied to the autonomic nervous system will contribute to elucidating its functional role in metabolism. Alternatively, teams may focus on novel approaches to address specific knowledge gaps or scientific questions that will significantly contribute to our understanding of role of the autonomic nervous system in metabolism with the goal of accelerating scientific progress in the treatment and prevention of metabolic disease.

Negotiable: Paramount Recruitment: Commercial Partnerships Manager Bioinformatics, Genomics, Central London - 100,000 Genomes Project - Commercial Division! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 City of London, England

Funding Opportunity RFA-MH-19-240 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits proposals for research projects that will apply computational approaches to develop parametrically detailed behavioral assays across mental-health relevant domains of function. These projects should focus on behavior in humans and test computational models in healthy subjects. For future applications, NIMH is particularly interested in behavioral measures, models, and parameters that have the potential for back-translation from humans to animals, especially for pre-clinical therapeutics development. NIMH is also interested in models that can be extended to clinical populations in the future.

Notice NOT-DK-18-022 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-18-012 from the NIH Guide for Grants and Contracts. Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits a single application for the continuation of the AIDS and Cancer Specimen Resource (ACSR). The eligible applicant institutions (which are the two current NCI-supported ACSR lead institutions) are expected to maintain the cooperative group structure and the activities of the ACSR. The primary objective of the ACSR will be to acquire, store, and equitably distribute tumor tissues, biological fluids, and associated demographic data from patients with human immunodeficiency virus (HIV)-associated malignancies. In addition to serving acquired immunodeficiency syndrome (AIDS) and cancer researchers at large, the ACSR will specifically provide biorepository functions for another NCI supported initiative, the AIDS Malignancy Consortium (AMC). The AMC performs clinical trials research in the treatment and prevention of HIV-associated malignancies in the United States and Sub-Saharan Africa. As the AMC is currently expanding its agenda to include Latin America, it is expected that the ACSR will collaborate with the AMC to develop regional biorepository support for AMC activities in Latin American countries. The continuing ACSR must have appropriate strategies and capabilities to address several high priority areas of specimen acquisition including specific types of cancer (AIDS-defining as well as non-AIDS defining), types of biospecimens and accompanying clinical data, and biospecimens from geographic areas of interest.

Areas of expertise may include bioinformatics, computational biology, computer vision, systems biology, synthetic biology, structural biology, biophysics,...
From University of Wyoming - Wed, 08 Aug 2018 21:52:26 GMT - View all Laramie, WY jobs

A cover letter, CV, contact information for three references, and two papers describing recent research....
From University of Wyoming - Wed, 08 Aug 2018 21:52:20 GMT - View all Laramie, WY jobs

Funding Opportunity PAR-18-895 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity is to support studies with a focus on developing drug delivery strategies that target the Central Nervous System (CNS) for better suppression of Human Immunodeficiency Virus (HIV) and reservoir reduction. Applications are sought proposing multidisciplinary efforts to enhance delivery of antiretroviral (ARV) drugs and biologics into CNS compartments, maintaining a good balance between therapeutic effect and toxicity. Collaborative research partnerships are strongly encouraged but not required.

Funding Opportunity PAR-18-894 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to enhance the diversity of the mental health research workforce by providing dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from backgrounds underrepresented in biomedical, behavioral, clinical and social sciences research. This award supports the completion of the doctoral research project.

Notice NOT-NS-18-082 from the NIH Guide for Grants and Contracts

Notice NOT-EB-18-023 from the NIH Guide for Grants and Contracts

Notice NOT-AG-18-024 from the NIH Guide for Grants and Contracts

Notice NOT-HG-18-014 from the NIH Guide for Grants and Contracts